SCHEMBL24255225

SCHEMBL24255225

Cc1ccc(CNc2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2Cl)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCND3 P30281 7/20 0.79
CDK6 Q00534 7/20 0.79
NTRK1 P04629 3/20 0.73
CCNK O75909 4/20 0.66
CDK9 P50750 4/20 0.66
ALK Q9UM73 2/20 0.66
JAK3 P52333 2/20 0.63
CCNA2 P20248 2/20 0.63
CDK2 P24941 2/20 0.63
NTRK3 Q16288 1/20 0.62
NTRK2 Q16620 1/20 0.62
TNK2 Q07912 3/20 0.61
STAT6 P42226 1/20 0.61
CHEK1 O14757 1/20 0.61
JAK2 O60674 1/20 0.61
ABL1 P00519 1/20 0.61
LCK P06239 1/20 0.61
ROS1 P08922 1/20 0.61
FGFR1 P11362 1/20 0.61
SRC P12931 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24255231 0.91 NTRK1 (0.81) CCND3CDK6NTRK1CCNKCDK9
SCHEMBL30393724 0.88 CCND3 (1.00) CCND3CDK6NTRK1CCNKCDK9
SCHEMBL17209773 0.85 JAK3 (0.83) NTRK1JAK3JAK2FGFR1SRC
SCHEMBL24255221 0.83 JAK3 (0.75) CCND3CDK6ALKJAK3TNK2
SCHEMBL18487871 0.83 NTRK1 (0.64) CCND3CDK6NTRK1CCNKCDK9
SCHEMBL18488287 0.81 CCND3 (0.80) CCND3CDK6NTRK1CCNKCDK9
SCHEMBL24255245 0.81 NTRK1 (0.66) CCND3CDK6NTRK1ALKJAK3
SCHEMBL18440651 0.81 ALK (0.74) CCND3CDK6NTRK1CCNKCDK9
SCHEMBL1607209 0.81 ALK (0.67) CCND3CDK6NTRK1CCNKCDK9
SCHEMBL23409133 0.80 ALK (0.72) CCND3CDK6NTRK1CCNKCDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295129-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE NATIONAL INSTITUTES OF HEALTH 2023-09-21 US disclosed
US-20230295129-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE NATIONAL INSTITUTES OF HEALTH 2023-09-21 US disclosed
WO-2022036312-A2 INHIBITORS OF ACK1/TNK1 TYROSINE KINASE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295129-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE TNK1, TNK2, TNNI3K CCND3 1813/4885CDK6 398/4885NTRK1 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.